Urinary MMPs/ADAM12 in Bladder Cancer

Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
Eissa S, Ali-Labib R, Swellam M, Bassiony M, Tash F, El-Zayat TM.
Eur Urol. 2007 Nov;52(5):1388-96. Epub 2007 Apr 10. (Published online ahead of print)

Molecular profiling of ADAM12 in human bladder cancer.
Fröhlich C, Albrechtsen R, Dyrskjøt L, Rudkjaer L, Ørntoft TF, Wewer UM.
Clin Cancer Res. 2006 Dec 15;12(24):7359-68.

Urinary MMPs/ADAM12 in Breast Cancer

The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients.
Fernández CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA.
Clin Cancer Res. 2005 Aug 1;11(15):5390-5.

ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage.
Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA.
J Biol Chem. 2004 Dec 3;279(49):51323-30. Epub 2004 Sep 20.

Urinary MMPs in Cancer

Increased incidence of matrix metalloproteinases in urine of cancer patients.
Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR.
Cancer Res. 1998 Apr 1;58(7):1395-9.

The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL.
Yan L, Borregaard N, Kjeldsen L, Moses MA.
J Biol Chem. 2001 Oct 5;276(40):37258-65. Epub 2001 Aug 2.

A recurrent craniopharyngioma illustrates the potential usefulness of urinary matrix metalloproteinases as noninvasive biomarkers: case report.
Smith ER, Manfredi M, Scott RM, Black PM, Moses MA.
Neurosurgery. 2007 Jun;60(6):E1148-9; discussion E1149.